Pliant Therapeutics
PLRX
92 hedge funds and large institutions have $222M invested in Pliant Therapeutics in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 35 increasing their positions, 21 reducing their positions, and 11 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 21
55% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 11
5% more funds holding
Funds holding: 88 → 92 (+4)
1.94% more ownership
Funds ownership: 85.61% → 87.55% (+1.9%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
47% less capital invested
Capital invested by funds: $416M → $222M (-$194M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Axa
Paris,
France
|
+$3.42M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$2.45M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$2.33M |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$2.21M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$1.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.73M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.37M |
| 3 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$810K |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$574K |
| 5 |
HF
HRT Financial
New York
|
-$530K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Simplex Trading
Chicago,
Illinois
| – | +$653 | +64 | New |
|
PLRX Hedge Fund Activity: Q1 2022 in Review
92 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q1 2022, worth a combined $222M — down 47% from $416M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new PLRX positions and 11 closed out — a net gain of 6 holders — while 35 added to existing stakes and 21 trimmed.
The largest buyer was Axa, opening a new position worth an estimated $3.42M. The largest seller was Point72 Asset Management, cutting an estimated $3.73M.
- 92 institutional investors held Pliant Therapeutics (PLRX) as of Q1 2022, up from 88 in Q4 2021.
- Funds reported $222M of Pliant Therapeutics stock for Q1 2022, down 47% quarter-over-quarter.
- 17 funds opened new Pliant Therapeutics positions in Q1 2022 and 11 closed out, a net change of +6 holders.
- The largest Pliant Therapeutics buyer in Q1 2022 was Axa, an estimated $3.42M added.
- The largest Pliant Therapeutics seller in Q1 2022 was Point72 Asset Management, an estimated $3.73M sold.
Based on aggregated 13F filings for Q1 2022.